

Bluechiip Investor Presentation

April 2015



Disclaimer

Material used in this presentation is a summary of available information, and while given in good faith, is professional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering investment in the company.

Certain information may have been derived from third parties and though BCT has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT. Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guarantee in relation to this presentation.

BCT reserves right to update, amend or supplement information in this presentation at any time in its absolute discretion without incurring any obligation to do so.

Bluechiip - Corporate Overview

Summary				
ASX Code	ВСТ			
Share Price	5.0c			
52 week range	3.1c - 16.0c			
Market Cap.	\$7.4m			
Net Cash	\$1.1m			
Enterprise Value	\$6.3m			

Share Price				
20c]		_	ſ	70m
			-	60m
15c -			-	50m
40-			-	40m
10c -				30m
5c -	~ /			20m
		Н.	-	10m
				_
Mar-14	Jun-14	Sep-14	Dec-14	


Board & Management		
Iain Kirkwood	Chairman	
Andrew McLellan	Managing Director	
Matthew Morgan	Non-Exec. Director	
Michael Ohanessian	Non-Exec. Director	

Major Shareholders			
Dr. Stephen Woodford	11.5%		
Chairman & Entities	6.4%		
3 rd Pulitano Pty Ltd	4.8%		
Roshi Blue Pty Ltd	4.1%		
Founder	3.3%		
Top 20 shareholders	45.9%		

Bluechiip - Vision

To be a leading global player in secure wireless tracking

For high value samples stored and transported in harsh environments, Bluechiip will be the tracking solution of choice with secure patented technologies that operate and measure temperatures to -196°C and survive gamma-irradiation



Bluechiip - Core Capabilities

Developed Core technology:

- Bluechiip has developed a MEMS based smart chip providing a unique patent-protected secure wireless tracking technology
- Bluechiip's smart chips have temperature sensing capabilities and other advanced features exceeding incumbent technologies in extreme environment situations such as biobanking applications
- Bluechiip readers and software have been developed to provide systems solutions
- Bluechiip is now focussed on commercialising globally via third party distribution and manufacturing and development under








MEMS - Micro Electro-Mechanical System

Bluechiip Initial Target Market





Biobanking – First Reference Application

Biobanking is the practice of **cryopreservation**: storing highly sensitive and precious biological samples and tissue for short and long periods of time

- Bio-preservation media & equipment market \$3.9B (2017)
 - Cryovials \$96.0m (2017), >350m samples
 - Blood transport bags
 - Regenerative medicine transportation











Stem Cells

IVF and Regenerative Medicine

Tissue and Pathology Samples

Clinical Trials

Pharmaceuticals

Strategic Priorities

Establishing global distribution channels

- Establishing market presence
- Reference site sales
- OEM identification and promotion


OEM Partnering and technology Licencing

- Accelerated market access through partner distribution
- Technology integration

Core technology feedback and reinforcement

- Capturing and responding to market feedback
- Pipeline of future opportunity

Distribution




Core Market Feedback — Validation and Distribution

- Bluechiip technology well known amongst biobank equipment suppliers
- Bluechiip technology is well differentiated with key benefits recognised by labs
- Biobanks are high throughput facilities
 - Millions of samples stored
 - Hundreds/thousands of samples per day
- Biobanks require high throughput solutions with time a key driver
 - Multi-vial reader
 - Handheld reader













Partnership / OEM — Progress and opportunities


- Bluechiip seeks to share in the success and risk of product sales by collaborating with Partners / OEM's to develop new innovative products in new markets
- Micronic Co-development agreement
 - Dual identity vials & multi-vial reader demonstrated at SLAS (Washington) Feb. 2015
 - 1st sale into Canada (starter kit)
 - Positive response & interest
- SIAD Blood bag trials in progress
- Opportunities progressing in regenerative medicine market







Partnering & Establishing Networks



Contact Details

Andrew McLellan

Managing Director & CEO andrew.mclellan@bluechiip.com +61 4 5782 3470